Total | Entonox | Midazolam | |
Number of patients recruited | 49 | ||
Entonox arm | 24 | ||
Midazolam arm | 22 | ||
Age (years) | |||
Mean | 61 | 64 | 59 |
Range | 30–90 | 33–90 | 30–84 |
Sex | |||
Male | 37 | 22 | 15 |
Female | 12 | 4 | 8 |
Diagnosis | |||
Pancytopenia | 1 | 1 | 0 |
Immune thrombocytopenia | 2 | 1 | 1 |
Acute myeloid leukaemia | 9 | 4 | 5 |
Lymphproliferative disorder | 18 | 9 | 9 |
Multiple myeloma | 8 | 5 | 3 |
Myeloproliferative disorder | 8 | 6 | 2 |
Myelofibrosis | 1 | 0 | 1 |
Myelodysplastic syndrome | 2 | 0 | 2 |
Number of patients who had previous BMAT | 17 | 6 | 11 |
Patients who had previous exposure to midazolam | 9/17 | 5 | 4 |
BMAT, bone marrow aspiration and trephine biopsy.